Quantifying Preferences in Drug Benefit‐Risk Decisions

Benefit‐risk assessment is used in various phases along the drug lifecycle, such as marketing authorization and surveillance, health technology assessment ( HTA ), and clinical decisions, to understand whether, and for which patients, a drug has a favorable or more valuable profile with reference to one or more comparators. Such assessments are inherently preference‐based as several clinical and nonclinical outcomes of varying importance might...